"The US Food and Drug Administration (FDA) has approved an injectable, long-acting version of Alkermes Inc's atypical antipsychotic aripiprazole to treat adults with schizophrenia.
Aripiprazole lauroxil (Aristada) is administere"...
The most frequently occurring effect is initial drowsiness that generally subsides with continued usage of the drug or lowering of the dose.
Extrapyramidal symptoms noted below may occur in susceptible individuals and are usually reversible with appropriate management.
Motor restlessness may occur early.
Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.
Antipsychotic drugs are known to cause a syndrome of dyskinetic movements commonly referred to as tardive dyskinesia. The movements may appear during treatment or upon withdrawal of treatment and may be either reversible or irreversible (i.e., persistent) upon cessation of further antipsychotic administration.
The syndrome is known to have a variable latency for development and the duration of the latency cannot be determined reliably. It is thus wise to assume that any antipsychotic agent has the capacity to induce the syndrome and act accordingly until sufficient data has been collected to settle the issue definitively for a specific drug product. In the case of antipsychotics known to produce the irreversible syndrome, the following has been observed.
Tardive dyskinesia has appeared in some patients on long-term therapy and has also appeared after drug therapy has been discontinued. The risk appears to be greater in elderly patients on high-dose therapy, especially females. The symptoms are persistent and in some patients appear to be irreversible. The syndrome is characterized by rhythmical involuntary movements of the tongue, face, mouth or jaw (e.g., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements). There may be involuntary movements of extremities.
There is no known effective treatment of tardive dyskinesia; antiparkinsonism agents usually do not alleviate the symptoms of this syndrome. It is suggested that all antipsychotic agents be discontinued if these symptoms appear. Should it be necessary to reinstitute treatment, or increase the dosage of the agent, or switch to a different antipsychotic agent, the syndrome may be masked. It has been reported that fine vermicular movements of the tongue may be an early sign of the syndrome and if the medication is stopped at that time the syndrome may not develop (See WARNINGS).
Autonomic Nervous System
Occasionally blurring of vision, tachycardia, nausea, dry mouth and salivation have been reported. Urinary retention and constipation may occur particularly if anticholinergic drugs are used to treat extrapyramidal symptoms. One patient being treated with MOBAN experienced priapism which required surgical intervention, apparently resulting in residual impairment of erectile function.
There have been rare reports of leucopenia and leucocytosis. If such reactions occur, treatment with MOBAN may continue if clinical symptoms are absent. Alterations of blood glucose, B.U.N., and red blood cells have not been considered clinically significant.
Metabolic And Endocrine Effects
Alteration of thyroid function has not been significant. Amenorrhea has been reported infrequently. Resumption of menses in previously amenorrheic women has been reported. Initially heavy menses may occur. Galactorrhea and gynecomastia have been reported infrequently. Increase in libido has been noted in some patients. Impotence has not been reported. Although both weight gain and weight loss have been in the direction of normal or ideal weight, excessive weight gain has not occurred with MOBAN.
There have been rare reports of clinically significant alterations in liver function in association with MOBAN use.
Rare, transient, non-specific T wave changes have been reported on E.K.G. Association with a clinical syndrome has not been established. Rarely has significant hypotension been reported.
Lens opacities and pigmentary retinopathy have not been reported where patients have received MOBAN. In some patients, phenothiazine induced lenticular opacities have resolved following discontinuation of the phenothiazine while continuing therapy with MOBAN.
Early, non-specific skin rash, probably of allergic origin, has occasionally been reported. Skin pigmentation has not been seen with MOBAN usage alone.
MOBAN has certain pharmacological similarities to other antipsychotic agents. Because adverse reactions are often extensions of the pharmacological activity of a drug, all of the known pharmacological effects associated with other antipsychotic drugs should be kept in mind when MOBAN is used. Upon abrupt withdrawal after prolonged high dosage an abstinence syndrome has not been noted.
Read the Moban (molindone hydrochloride tablets) Side Effects Center for a complete guide to possible side effects
Potentiation of drugs administered concurrently with MOBAN has not been reported. Additionally, animal studies have not shown increased toxicity when MOBAN is given concurrently with representative members of three classes of drugs (i.e., barbiturates, chloral hydrate and antiparkinson drugs).
Studies in pregnant patients have not been carried out. Reproduction studies have been performed in the following animals:
Pregnant Rats Oral Dose
no adverse effect: 20 mg/kg/day -10 days
no adverse effect: 40 mg/kg/day -10 days
Pregnant Mice Oral Dose
slight increase resorptions: 20 mg/kg/day -10 days
slight increase resorptions: 40 mg/kg/day -10 days
Pregnant Rabbits Oral Dose
no adverse effect: 5 mg/kg/day -12 days
no adverse effect: 10 mg/kg/day -12 days
no adverse effect: 20 mg/kg/day -12 days
Animal reproductive studies have not demonstrated a teratogenic potential. The anticipated benefits must be weighed against the unknown risks to the fetus if used in pregnant patients.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 3/20/2017
Additional Moban Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on therapy and treatment.